ProCyto Labs has been recognized as the winner of the SEVA Innovation Challenge for its innovative drug and preservative-free allergen-blocking eye gel, developed to address the needs of individuals suffering from chronic eye allergies, irritation, and Vernal Keratoconjunctivitis (VKC). Designed to provide long-lasting relief from ocular allergy-related discomfort, the novel eye formulation reflects the company’s commitment to developing accessible and impactful healthcare solutions. The recognition marks an important milestone in the development of the formulation and acknowledges its potential to address a significant unmet need in ocular healthcare. This achievement marks a significant milestone for the team and strengthens our commitment to innovative healthcare solutions.
ProCyto Labs Wins the SEVA Innovation Challenge for Its Novel Eye Formulation
